挪威 - 挪威文 - Statens legemiddelverk

janssen-cilag as - fentanyl - depotplaster - 75 mikrog/ time

挪威 - 挪威文 - Statens legemiddelverk

janssen-cilag as - fentanyl - depotplaster - 100 mikrog/ time

挪威 - 挪威文 - Statens legemiddelverk

dr. falk pharma gmbh - ursodeoksykolsyre - mikstur, suspensjon med sitronsmak - 50 mg/ ml

欧盟 - 挪威文 - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuri, paroksysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

欧盟 - 挪威文 - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - andre antianemic preparations - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

挪威 - 挪威文 - Statens legemiddelverk

amomed pharma gmbh - landiololhydroklorid - pulver til infusjonsvæske, oppløsning - 300 mg

挪威 - 挪威文 - Statens legemiddelverk

ratiopharm gmbh - fentanyl - depotplaster - 75 mikrog/ time

挪威 - 挪威文 - Statens legemiddelverk

ratiopharm gmbh - fentanyl - depotplaster - 12 mikrog/ time

挪威 - 挪威文 - Statens legemiddelverk

ratiopharm gmbh - fentanyl - depotplaster - 25 mikrog/ time

挪威 - 挪威文 - Statens legemiddelverk

ratiopharm gmbh - fentanyl - depotplaster - 50 mikrog/ time